This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the role of IL-17 in Systemic Sclerosis with a focus on LUMICEF (brodalumab)
Ticker(s): KYKOF, AZN, ZURA, KY4.XFRAWho's the expert?
Institution: Singing River Health System
- Board certified Rheumatologist in clinical practice for 18+ years.
- Manages 1200 RA patients, 450 PsA patients, and 45-50 scleroderma patients in a non-academic community hospital system.
Interview GoalOn this call, we will discuss the role of IL-17 in systemic sclerosis, focusing on its contribution to inflammation and fibrosis and explore potential therapeutic approaches targeting IL-17, examining ongoing research and the promise of IL-17 inhibitors in improving patient outcomes and quality of life in systemic sclerosis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
